FDA Clears Identification of Mycobacteria, Nocardia and Moulds on VITEK® MS

bioMérieux have announced that VITEK® MS, its MALDI-TOF Mass Spectrometry System for rapid pathogen identification, has received 510(k) clearance from the FDA for the expanded identification of mycobacteria, Nocardia and moulds. This database includes more than 15,000 distinct strains to provide extremely high accuracy and, for the first time, enables the safe identification of the Mycobacterium tuberculosis (TB) group, the most frequent non-tuberculous mycobacteria (NTM), Nocardia and the most medically important moulds. The VITEK® MS system’s newly expanded database and Mycobacterium/Nocardia and Moulds reagent kits are now commercially available in the U.S.

Mycobacteria, Nocardia and moulds are complex organisms to identify, requiring days or weeks of specific culture conditions for appropriate growth and subsequent advanced methods for reliable identification to the species level. With the newly expanded database, bioMérieux’s VITEK® MS system now offers simple, rapid, safe and reliable identification of these medically important pathogens, providing clinicians with actionable results to better manage these infections, such as tuberculosis, lung and bone infections, and other serious organ infections.

To gain new FDA clearance for these new species, bioMérieux submitted data from a multi-center study consisting of 2,695 clinical isolates for 47 moulds, 19 mycobacteria, and 12 Nocardia. The FDA clearance of Mycobacterium species was from both solid and liquid growth media.

VITEK® MS is part of bioMérieux’s comprehensive and complementary range of ID/AST solutions for infectious disease diagnostics. Together, VITEK® MS for identification and VITEK® 2 for antimicrobial susceptibility testing provide seamless integration and the flexibility needed to optimize laboratory workflow and support appropriate antimicrobial treatment decisions. The combination of VITEK®MS and VITEK® 2 provides confidence in reporting results with speed and accuracy for routine diagnoses, unusual or resistant organisms, or critical clinical situations.

In cases where microorganisms are resistant to carbapenems (a very broad spectrum antibiotic class), bioMérieux has also developed and received FDA 510(k) clearance for its RAPIDEC® CARBA NP test that enables the detection of carbapenemase producers within two hours. RAPIDEC® CARBA NP helps health professionals make vital treatment decisions and facilitates implementation of infection prevention and control measures.


     
Tags: Carbapenemase Resistant Enterobacteriaceae (CRE), Identification, Mycobacterium, Yeasts & Moulds, MALDI-TOF, Mycobacterium tuberculosis, Nocardia

Date Published: August 1, 2017

Source article link: bioMérieux (Clinical Diagnostics) » company contact details

bioMérieux (clinical diagnostic applications)

Marcy L'Etoile

France

Email:

Tel: +[33] 4 78 87 20 00


Related news from
bioMérieux (clinical diagnostic applications):

Company general:



© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed